» Articles » PMID: 18549850

Emerging Cardiovascular Risk Factors That Account for a Significant Portion of Attributable Mortality Risk in Chronic Kidney Disease

Overview
Journal Am J Cardiol
Date 2008 Jun 14
PMID 18549850
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic kidney disease (CKD) increases cardiovascular risk and mortality. However, traditional cardiovascular risk factors do not adequately account for the substantial increase in mortality observed in CKD. The aim of this study was to examine the relative contributions of novel cardiovascular risk factors to the risk between CKD and mortality. The study population included 4,680 consecutive new patients from a tertiary care preventive cardiology program from 1996 to 2005. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease (MDRD) method. Baseline levels of traditional (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, hypertension, triglycerides, total cholesterol, and fasting glucose) and emerging (apolipoproteins A-I and B, lipoprotein[a], fibrinogen, homocysteine, and high-sensitivity C-reactive protein) risk factors were examined. All-cause mortality was obtained from the Social Security Death Index. There were 278 deaths over a median follow-up period of 22 months. CKD (estimated glomerular filtration rate <or=60 ml/min/1.73 m(2)) was strongly associated with mortality after adjusting for traditional cardiovascular risk factors (hazard ratio 2.31, 95% confidence interval 1.77 to 3.11, p<0.001) and with the addition of propensity score (hazard ratio 2.33, 95% confidence interval 1.75 to 3.10, p<0.001). Of all the traditional and emerging risk factors monitored, only the addition of homocysteine and fibrinogen significantly attenuated the association between CKD and mortality (adjusted hazard ratio 1.73, 95% confidence interval 1.23 to 2.34, p<0.001), explaining 38% of the attributable mortality risk from CKD. A significant interaction (p=0.004) between homocysteine and estimated glomerular filtration rate was observed whereby the annual mortality rate in subjects with CKD with homocysteine <10 micromol/L (the bottom tertile) was similar to those with normal renal function (1% per year), whereas homocysteine levels >or=12.5 micromol/L (the top tertile) were associated with a sevenfold greater mortality risk. In conclusion, homocysteine and fibrinogen levels explain nearly 40% of the attributable mortality risk from CKD.

Citing Articles

Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility.

Villanueva S, Gonzalez F, Lorca E, Tapia A, Lopez V, Strodthoff R Kidney Res Clin Pract. 2019; 38(2):176-185.

PMID: 31189223 PMC: 6577210. DOI: 10.23876/j.krcp.18.0139.


Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis.

Schuett K, Savvaidis A, Maxeiner S, Lysaja K, Jankowski V, Schirmer S J Am Soc Nephrol. 2017; 28(5):1622-1630.

PMID: 28057772 PMC: 5407718. DOI: 10.1681/ASN.2016030336.


Baroreflex dysfunction in chronic kidney disease.

Kaur M, Chandran D, Jaryal A, Bhowmik D, Agarwal S, Deepak K World J Nephrol. 2016; 5(1):53-65.

PMID: 26788464 PMC: 4707168. DOI: 10.5527/wjn.v5.i1.53.


Residual Associations of Inflammatory Markers with eGFR after Accounting for Measured GFR in a Community-Based Cohort without CKD.

Schei J, Stefansson V, Mathisen U, Eriksen B, Solbu M, Jenssen T Clin J Am Soc Nephrol. 2015; 11(2):280-6.

PMID: 26668020 PMC: 4741046. DOI: 10.2215/CJN.07360715.


Why do young people with chronic kidney disease die early?.

Kumar S, Bogle R, Banerjee D World J Nephrol. 2014; 3(4):143-55.

PMID: 25374808 PMC: 4220347. DOI: 10.5527/wjn.v3.i4.143.


References
1.
Shlipak M, Fried L, Crump C, Bleyer A, Manolio T, Tracy R . Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1):87-92. DOI: 10.1161/01.cir.0000042700.48769.59. View

2.
van Guldener C . Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?. Nephrol Dial Transplant. 2006; 21(5):1161-6. DOI: 10.1093/ndt/gfl044. View

3.
Hoffer L . Testing the homocysteine hypothesis in end-stage renal disease: Problems and a possible solution. Kidney Int. 2006; 69(9):1507-10. DOI: 10.1038/sj.ki.5000279. View

4.
Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen A, Gausson V, Mothu N . Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2005; 45(1):39-47. DOI: 10.1053/j.ajkd.2004.09.011. View

5.
Shishehbor M, Litaker D, Pothier C, Lauer M . Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA. 2006; 295(7):784-92. DOI: 10.1001/jama.295.7.784. View